EU regulator backs Eisai-Biogen Alzheimer’s drug
EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific patient group.
The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheim...
Read More
Other Stories in Health
- New advisory offers evidence-based strategies to prevent postoperative delirium in older adults
- Wheat flour or Ragi flour: Which one is healthier?
- Keynote Selena Gomez spotlights prioritizing mental health during Academy Women's Luncheon
- UVM scientists discover new mechanism for blood flow regulation in the brain
- More cancer patients die here than in US, South Korea, Japan: Paper
- 'Yellowstone' Season 5 Episode 13 Recap: What Happened?
- Route to Christmas: Day 9 2024
- Depression genes amplify women's heart disease risk
- Measles & Rubella Weekly Monitoring Report – Week 20: May 12 to May 18, 2024
.png)
